Developments towards antiviral therapies against enterovirus 71
Related Experiment Video
Updated: Jun 7, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Kan X Wu1, Mary M-L Ng, Justin J H Chu
1Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System, 5 Science Drive 2, National University of Singapore, Singapore.
Abstract:
Enterovirus 71 (EV71) has emerged as a clinically important neurotropic virus that can cause acute flaccid paralysis and encephalitis, leading to cardiopulmonary failure and death. Recurring outbreaks of EV71 have been reported in several countries. The current lack of approved anti-EV71 therapy has prompted intense research into antiviral development. Several strategies--ranging from target-based chemical design to compound library screenings--have been employed, while others revisited compound series generated from antiviral developments against poliovirus and human rhinoviruses. These efforts have given rise to a diversity of antiviral candidates that include small molecules and non-conventional nucleic-acid-based strategies. This review aims to highlight candidates with potential for further clinical development based on their putative modes of action.
Related Concept Videos
Respiratory Syncytial Virus Disease
Antiviral Nucleoside Inhibitors
Poliomyelitis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly

